Page 33 - 2021_05-Haematologica-web

Persistence of myelofibrosis treated with ruxolitinib
after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243-1252.
70. Gisslinger H, Schalling M, Gisslinger B, Skrabs C, Mullauer L, Kralovics R. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol. 2014;89(3): 344-346.
71. Gerds A, Su D, Martynova A, et al. Ruxolitinib rechallenge can improve consti- tutional symptoms and splenomegaly in patients with myelofibrosis: a case series. Clin Lymphoma Myeloma Leuk. 2018;18 (11):e463-e468.
72. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
73. Mascarenhas JO, Talpaz M, Gupta V, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102(2):327-335.
74. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a
randomized clinical trial. JAMA Oncol.
2015;1(5):643-651.
75.Soverini S, Colarossi S, Gnani A, et al.
Contribution of ABL kinase domain muta- tions to imatinib resistance in different sub- sets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374-7379.
76. Sadras T, Heatley SL, Kok CH, et al. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genet. 2017;216-217:86-90.
77. Kesarwani M, Huber E, Kincaid Z, et al. Targeting substrate-site in Jak2 kinase pre- vents emergence of genetic resistance. Sci Rep. 2015;5:14538.
78. Evans EK, Gardino AK, Kim JL, et al. A pre- cision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;9(414):eaao1690.
79. Hammaren HM, Ungureanu D, Grisouard J, Skoda RC, Hubbard SR, Silvennoinen O. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015;112(15): 4642-4647.
80. Bhagwat N, Koppikar P, Keller M, et al.
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloprolif- erative neoplasms. Blood. 2014;123(13): 2075-2083.
81.Hobbs GS, Hanasoge Somasundara AV, Kleppe M, et al. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myelopro- liferative neoplasms. Haematologica. 2018;103(1):e5-e9.
82. Johnson ML, Yu HA, Hart EM, et al. Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth fac- tor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33(15):1666-1673.
83. Shah RR, Redmond JM, Mihut A, et al. Hi- JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs. Bioorg Med Chem. 2020;28(5): 115326.
84. Akiyama H, Umezawa Y, Watanabe D, et al. Inhibition of USP9X downregulates JAK2- V617F and induces apoptosis synergistically with BH3 mimetics preferentially in ruxoli- tinib-persistent JAK2-V617F-positive leukemic cells. Cancers (Basel). 2020;12(2): 406.
haematologica | 2021; 106(5)
1253